1	One	_	CD	_	_	2	NMOD	_	_
2	day	_	NN	_	_	22	TMP	_	_
3	after	_	IN	_	_	2	TMP	_	_
4	Delmed	_	NNP	_	_	6	SBJ	_	_
5	Inc.	_	NNP	_	_	4	POSTHON	_	_
6	made	_	VBD	_	_	3	SUB	_	_
7	top	_	JJ	_	_	9	NMOD	_	_
8	management	_	NN	_	_	9	NMOD	_	_
9	changes	_	NNS	_	_	6	OBJ	_	_
10	and	_	CC	_	_	6	COORD	_	_
11	disclosed	_	VBD	_	_	10	CONJ	_	_
12	the	_	DT	_	_	13	NMOD	_	_
13	end	_	NN	_	_	11	OBJ	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	an	_	DT	_	_	18	NMOD	_	_
16	important	_	JJ	_	_	18	NMOD	_	_
17	business	_	NN	_	_	18	NMOD	_	_
18	tie	_	NN	_	_	14	PMOD	_	_
19	,	_	,	_	_	22	P	_	_
20	its	_	PRP$	_	_	21	NMOD	_	_
21	stock	_	NN	_	_	22	SBJ	_	_
22	did	_	VBD	_	_	0	ROOT	_	_
23	n't	_	RB	_	_	22	ADV	_	_
24	trade	_	VB	_	_	22	VC	_	_
25	and	_	CC	_	_	22	COORD	_	_
26	the	_	DT	_	_	27	NMOD	_	_
27	company	_	NN	_	_	28	SBJ	_	_
28	forecast	_	VBD	_	_	25	CONJ	_	_
29	a	_	DT	_	_	33	NMOD	_	_
30	``	_	``	_	_	33	P	_	_
31	significant	_	JJ	_	_	33	NMOD	_	_
32	''	_	''	_	_	33	P	_	_
33	drop	_	NN	_	_	28	OBJ	_	_
34	next	_	JJ	_	_	35	NMOD	_	_
35	year	_	NN	_	_	33	TMP	_	_
36	in	_	IN	_	_	33	NMOD	_	_
37	sales	_	NNS	_	_	36	PMOD	_	_
38	of	_	IN	_	_	37	NMOD	_	_
39	its	_	PRP$	_	_	41	NMOD	_	_
40	core	_	NN	_	_	41	NMOD	_	_
41	product	_	NN	_	_	38	PMOD	_	_
42	.	_	.	_	_	22	P	_	_

1	That	_	DT	_	_	2	NMOD	_	_
2	disclosure	_	NN	_	_	3	SBJ	_	_
3	came	_	VBD	_	_	8	OBJ	_	_
4	,	_	,	_	_	8	P	_	_
5	a	_	DT	_	_	7	NMOD	_	_
6	Delmed	_	NNP	_	_	7	NMOD	_	_
7	spokeswoman	_	NN	_	_	8	SBJ	_	_
8	said	_	VBD	_	_	0	ROOT	_	_
9	,	_	,	_	_	8	P	_	_
10	after	_	IN	_	_	3	TMP	_	_
11	the	_	DT	_	_	14	NMOD	_	_
12	American	_	NNP	_	_	14	NAME	_	_
13	Stock	_	NNP	_	_	14	NAME	_	_
14	Exchange	_	NNP	_	_	15	SBJ	_	_
15	alerted	_	VBD	_	_	10	SUB	_	_
16	the	_	DT	_	_	17	NMOD	_	_
17	company	_	NN	_	_	15	OBJ	_	_
18	that	_	IN	_	_	15	OBJ	_	_
19	trading	_	NN	_	_	20	SBJ	_	_
20	would	_	MD	_	_	18	SUB	_	_
21	n't	_	RB	_	_	20	ADV	_	_
22	resume	_	VB	_	_	20	VC	_	_
23	in	_	IN	_	_	22	LOC	_	_
24	its	_	PRP$	_	_	25	NMOD	_	_
25	stock	_	NN	_	_	23	PMOD	_	_
26	until	_	IN	_	_	22	TMP	_	_
27	additional	_	JJ	_	_	28	NMOD	_	_
28	information	_	NN	_	_	31	SBJ	_	_
29	about	_	IN	_	_	28	NMOD	_	_
30	developments	_	NNS	_	_	29	PMOD	_	_
31	was	_	VBD	_	_	26	SUB	_	_
32	provided	_	VBN	_	_	31	VC	_	_
33	.	_	.	_	_	3	P	_	_

1	In	_	IN	_	_	10	ADV	_	_
2	addition	_	NN	_	_	1	PMOD	_	_
3	to	_	TO	_	_	2	NMOD	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	forecast	_	NN	_	_	3	PMOD	_	_
6	,	_	,	_	_	10	P	_	_
7	the	_	DT	_	_	8	NMOD	_	_
8	company	_	NN	_	_	10	SBJ	_	_
9	also	_	RB	_	_	10	ADV	_	_
10	said	_	VBD	_	_	0	ROOT	_	_
11	it	_	PRP	_	_	12	SBJ	_	_
12	is	_	VBZ	_	_	10	OBJ	_	_
13	examining	_	VBG	_	_	12	VC	_	_
14	potential	_	JJ	_	_	16	NMOD	_	_
15	cost	_	NN	_	_	16	NMOD	_	_
16	cuts	_	NNS	_	_	13	OBJ	_	_
17	and	_	CC	_	_	16	COORD	_	_
18	reductions	_	NNS	_	_	17	CONJ	_	_
19	in	_	IN	_	_	18	LOC	_	_
20	overhead	_	NN	_	_	19	PMOD	_	_
21	.	_	.	_	_	10	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	spokeswoman	_	NN	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	exchange	_	NN	_	_	6	SBJ	_	_
6	would	_	MD	_	_	3	OBJ	_	_
7	resume	_	VB	_	_	6	VC	_	_
8	trading	_	VBG	_	_	7	OBJ	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	Delmed	_	NNP	_	_	11	NMOD	_	_
11	stock	_	NN	_	_	9	PMOD	_	_
12	today	_	NN	_	_	7	TMP	_	_
13	.	_	.	_	_	3	P	_	_

1	Delmed	_	NNP	_	_	18	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	which	_	WDT	_	_	4	SBJ	_	_
4	makes	_	VBZ	_	_	1	NMOD	_	_
5	and	_	CC	_	_	4	COORD	_	_
6	sells	_	VBZ	_	_	5	CONJ	_	_
7	peritoneal	_	JJ	_	_	9	NMOD	_	_
8	dialysis	_	NN	_	_	9	NMOD	_	_
9	products	_	NNS	_	_	4	OBJ	_	_
10	used	_	VBN	_	_	9	APPO	_	_
11	in	_	IN	_	_	10	LOC	_	_
12	treating	_	VBG	_	_	11	PMOD	_	_
13	kidney	_	NN	_	_	14	NMOD	_	_
14	disease	_	NN	_	_	12	OBJ	_	_
15	,	_	,	_	_	1	P	_	_
16	on	_	IN	_	_	18	TMP	_	_
17	Tuesday	_	NNP	_	_	16	PMOD	_	_
18	announced	_	VBD	_	_	0	ROOT	_	_
19	the	_	DT	_	_	20	NMOD	_	_
20	resignations	_	NNS	_	_	18	OBJ	_	_
21	of	_	IN	_	_	20	NMOD	_	_
22	Robert	_	NNP	_	_	24	NAME	_	_
23	S.	_	NNP	_	_	24	NAME	_	_
24	Ehrlich	_	NNP	_	_	21	PMOD	_	_
25	,	_	,	_	_	24	P	_	_
26	chairman	_	NN	_	_	24	APPO	_	_
27	,	_	,	_	_	26	P	_	_
28	president	_	NN	_	_	26	COORD	_	_
29	and	_	CC	_	_	28	COORD	_	_
30	chief	_	NN	_	_	32	NMOD	_	_
31	executive	_	NN	_	_	32	NMOD	_	_
32	officer	_	NN	_	_	29	CONJ	_	_
33	,	_	,	_	_	24	P	_	_
34	and	_	CC	_	_	21	COORD	_	_
35	of	_	IN	_	_	34	CONJ	_	_
36	Leslie	_	NNP	_	_	38	NAME	_	_
37	I.	_	NNP	_	_	38	NAME	_	_
38	Shapiro	_	NNP	_	_	35	PMOD	_	_
39	,	_	,	_	_	38	P	_	_
40	chief	_	NN	_	_	42	NMOD	_	_
41	operating	_	VBG	_	_	42	NMOD	_	_
42	officer	_	NN	_	_	38	APPO	_	_
43	and	_	CC	_	_	42	COORD	_	_
44	chief	_	NN	_	_	46	NMOD	_	_
45	financial	_	JJ	_	_	46	NMOD	_	_
46	officer	_	NN	_	_	43	CONJ	_	_
47	.	_	.	_	_	18	P	_	_

1	They	_	PRP	_	_	2	SBJ	_	_
2	were	_	VBD	_	_	0	ROOT	_	_
3	succeeded	_	VBN	_	_	2	VC	_	_
4	by	_	IN	_	_	3	LGS	_	_
5	executives	_	NNS	_	_	4	PMOD	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	Fresenius	_	NNP	_	_	8	NAME	_	_
8	USA	_	NNP	_	_	6	PMOD	_	_
9	Inc.	_	NNP	_	_	8	POSTHON	_	_
10	and	_	CC	_	_	8	COORD	_	_
11	its	_	PRP$	_	_	12	NMOD	_	_
12	parent	_	NN	_	_	10	CONJ	_	_
13	,	_	,	_	_	12	P	_	_
14	Fresenius	_	NNP	_	_	15	NAME	_	_
15	AG	_	NNP	_	_	12	APPO	_	_
16	,	_	,	_	_	12	P	_	_
17	which	_	WDT	_	_	18	SBJ	_	_
18	owns	_	VBZ	_	_	12	NMOD	_	_
19	about	_	IN	_	_	20	DEP	_	_
20	45	_	CD	_	_	21	NMOD	_	_
21	%	_	NN	_	_	18	OBJ	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	Delmed	_	NNP	_	_	22	PMOD	_	_
24	.	_	.	_	_	2	P	_	_

1	At	_	IN	_	_	13	TMP	_	_
2	the	_	DT	_	_	4	NMOD	_	_
3	same	_	JJ	_	_	4	NMOD	_	_
4	time	_	NN	_	_	1	PMOD	_	_
5	,	_	,	_	_	13	P	_	_
6	the	_	DT	_	_	12	NMOD	_	_
7	New	_	NNP	_	_	10	NAME	_	_
8	Brunswick	_	NNP	_	_	10	NAME	_	_
9	,	_	,	_	_	10	P	_	_
10	N.J.	_	NNP	_	_	12	LOC	_	_
11	,	_	,	_	_	10	P	_	_
12	company	_	NN	_	_	13	SBJ	_	_
13	said	_	VBD	_	_	0	ROOT	_	_
14	negotiations	_	NNS	_	_	21	SBJ	_	_
15	about	_	IN	_	_	14	NMOD	_	_
16	pricing	_	VBG	_	_	15	PMOD	_	_
17	and	_	CC	_	_	16	COORD	_	_
18	volumes	_	NNS	_	_	17	CONJ	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	product	_	NN	_	_	19	PMOD	_	_
21	had	_	VBD	_	_	13	OBJ	_	_
22	collapsed	_	VBN	_	_	21	VC	_	_
23	between	_	IN	_	_	14	NMOD	_	_
24	it	_	PRP	_	_	23	PMOD	_	_
25	and	_	CC	_	_	24	COORD	_	_
26	its	_	PRP$	_	_	28	NMOD	_	_
27	exclusive	_	JJ	_	_	28	NMOD	_	_
28	distributor	_	NN	_	_	25	CONJ	_	_
29	in	_	IN	_	_	28	LOC	_	_
30	the	_	DT	_	_	31	NMOD	_	_
31	U.S.	_	NNP	_	_	29	PMOD	_	_
32	,	_	,	_	_	28	P	_	_
33	National	_	NNP	_	_	35	NAME	_	_
34	Medical	_	NNP	_	_	35	NAME	_	_
35	Care	_	NNP	_	_	28	APPO	_	_
36	Inc	_	NNP	_	_	35	POSTHON	_	_
37	.	_	.	_	_	13	P	_	_

1	Following	_	VBG	_	_	10	TMP	_	_
2	that	_	DT	_	_	3	NMOD	_	_
3	announcement	_	NN	_	_	1	PMOD	_	_
4	Tuesday	_	NNP	_	_	3	TMP	_	_
5	,	_	,	_	_	10	P	_	_
6	however	_	RB	_	_	10	ADV	_	_
7	,	_	,	_	_	10	P	_	_
8	company	_	NN	_	_	9	NMOD	_	_
9	officials	_	NNS	_	_	10	SBJ	_	_
10	were	_	VBD	_	_	0	ROOT	_	_
11	unavailable	_	JJ	_	_	10	PRD	_	_
12	to	_	TO	_	_	11	AMOD	_	_
13	elaborate	_	VB	_	_	12	IM	_	_
14	.	_	.	_	_	10	P	_	_

1	Yesterday	_	NN	_	_	5	TMP	_	_
2	,	_	,	_	_	5	P	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	spokeswoman	_	NN	_	_	5	SBJ	_	_
5	said	_	VBD	_	_	0	ROOT	_	_
6	sales	_	NNS	_	_	17	SBJ	_	_
7	of	_	IN	_	_	6	NMOD	_	_
8	Delmed	_	NNP	_	_	9	NMOD	_	_
9	products	_	NNS	_	_	7	PMOD	_	_
10	through	_	IN	_	_	6	NMOD	_	_
11	the	_	DT	_	_	13	NMOD	_	_
12	exclusive	_	JJ	_	_	13	NMOD	_	_
13	arrangement	_	NN	_	_	10	PMOD	_	_
14	with	_	IN	_	_	13	NMOD	_	_
15	National	_	NNP	_	_	16	NAME	_	_
16	Medical	_	NNP	_	_	14	PMOD	_	_
17	accounted	_	VBD	_	_	5	OBJ	_	_
18	for	_	IN	_	_	17	ADV	_	_
19	87	_	CD	_	_	20	NMOD	_	_
20	%	_	NN	_	_	18	PMOD	_	_
21	of	_	IN	_	_	20	NMOD	_	_
22	Delmed	_	NNP	_	_	25	NMOD	_	_
23	's	_	POS	_	_	22	SUFFIX	_	_
24	1988	_	CD	_	_	25	NMOD	_	_
25	sales	_	NNS	_	_	21	PMOD	_	_
26	of	_	IN	_	_	25	NMOD	_	_
27	$	_	$	_	_	26	PMOD	_	_
28	21.1	_	CD	_	_	27	DEP	_	_
29	million	_	CD	_	_	27	DEP	_	_
30	.	_	.	_	_	5	P	_	_

1	The	_	DT	_	_	4	NMOD	_	_
2	current	_	JJ	_	_	4	NMOD	_	_
3	distribution	_	NN	_	_	4	NMOD	_	_
4	arrangement	_	NN	_	_	5	SBJ	_	_
5	ends	_	VBZ	_	_	31	OBJ	_	_
6	in	_	IN	_	_	5	TMP	_	_
7	March	_	NNP	_	_	6	PMOD	_	_
8	1990	_	CD	_	_	7	NMOD	_	_
9	,	_	,	_	_	5	P	_	_
10	although	_	IN	_	_	5	ADV	_	_
11	Delmed	_	NNP	_	_	12	SBJ	_	_
12	said	_	VBD	_	_	10	SUB	_	_
13	it	_	PRP	_	_	14	SBJ	_	_
14	will	_	MD	_	_	12	OBJ	_	_
15	continue	_	VB	_	_	14	VC	_	_
16	to	_	TO	_	_	15	OPRD	_	_
17	provide	_	VB	_	_	16	IM	_	_
18	some	_	DT	_	_	19	NMOD	_	_
19	supplies	_	NNS	_	_	17	OBJ	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	the	_	DT	_	_	24	NMOD	_	_
22	peritoneal	_	JJ	_	_	24	NMOD	_	_
23	dialysis	_	NN	_	_	24	NMOD	_	_
24	products	_	NNS	_	_	20	PMOD	_	_
25	to	_	TO	_	_	17	DTV	_	_
26	National	_	NNP	_	_	27	NAME	_	_
27	Medical	_	NNP	_	_	25	PMOD	_	_
28	,	_	,	_	_	31	P	_	_
29	the	_	DT	_	_	30	NMOD	_	_
30	spokeswoman	_	NN	_	_	31	SBJ	_	_
31	said	_	VBD	_	_	0	ROOT	_	_
32	.	_	.	_	_	31	P	_	_

1	Nonetheless	_	RB	_	_	6	ADV	_	_
2	,	_	,	_	_	6	P	_	_
3	``	_	``	_	_	6	P	_	_
4	Delmed	_	NNP	_	_	6	SBJ	_	_
5	currently	_	RB	_	_	6	TMP	_	_
6	expects	_	VBZ	_	_	22	OBJ	_	_
7	that	_	IN	_	_	6	OBJ	_	_
8	1990	_	CD	_	_	9	NMOD	_	_
9	sales	_	NNS	_	_	11	SBJ	_	_
10	...	_	:	_	_	11	P	_	_
11	will	_	MD	_	_	7	SUB	_	_
12	be	_	VB	_	_	11	VC	_	_
13	significantly	_	RB	_	_	14	DEP	_	_
14	below	_	IN	_	_	12	PRD	_	_
15	their	_	PRP$	_	_	17	NMOD	_	_
16	1989	_	CD	_	_	17	NMOD	_	_
17	level	_	NN	_	_	14	PMOD	_	_
18	,	_	,	_	_	22	P	_	_
19	''	_	''	_	_	22	P	_	_
20	the	_	DT	_	_	21	NMOD	_	_
21	company	_	NN	_	_	22	SBJ	_	_
22	said	_	VBD	_	_	0	ROOT	_	_
23	in	_	IN	_	_	22	LOC	_	_
24	a	_	DT	_	_	25	NMOD	_	_
25	statement	_	NN	_	_	23	PMOD	_	_
26	.	_	.	_	_	22	P	_	_

1	Delmed	_	NNP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	yesterday	_	NN	_	_	2	TMP	_	_
4	that	_	IN	_	_	2	OBJ	_	_
5	Fresenius	_	NNP	_	_	6	NAME	_	_
6	USA	_	NNP	_	_	7	SBJ	_	_
7	would	_	MD	_	_	4	SUB	_	_
8	begin	_	VB	_	_	7	VC	_	_
9	distributing	_	VBG	_	_	8	OPRD	_	_
10	the	_	DT	_	_	11	NMOD	_	_
11	product	_	NN	_	_	9	OBJ	_	_
12	and	_	CC	_	_	4	COORD	_	_
13	that	_	IN	_	_	12	CONJ	_	_
14	the	_	DT	_	_	15	NMOD	_	_
15	company	_	NN	_	_	16	SBJ	_	_
16	is	_	VBZ	_	_	13	SUB	_	_
17	investigating	_	VBG	_	_	16	VC	_	_
18	other	_	JJ	_	_	21	NMOD	_	_
19	possible	_	JJ	_	_	21	NMOD	_	_
20	distribution	_	NN	_	_	21	NMOD	_	_
21	channels	_	NNS	_	_	17	OBJ	_	_
22	.	_	.	_	_	2	P	_	_

1	In	_	IN	_	_	8	ADV	_	_
2	any	_	DT	_	_	3	NMOD	_	_
3	case	_	NN	_	_	1	PMOD	_	_
4	,	_	,	_	_	8	P	_	_
5	supplies	_	NNS	_	_	8	SBJ	_	_
6	to	_	TO	_	_	5	NMOD	_	_
7	patients	_	NNS	_	_	6	PMOD	_	_
8	wo	_	MD	_	_	15	OBJ	_	_
9	n't	_	RB	_	_	8	ADV	_	_
10	be	_	VB	_	_	8	VC	_	_
11	interrupted	_	VBN	_	_	10	VC	_	_
12	,	_	,	_	_	15	P	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	company	_	NN	_	_	15	SBJ	_	_
15	added	_	VBD	_	_	0	ROOT	_	_
16	.	_	.	_	_	15	P	_	_

1	Fresenius	_	NNP	_	_	9	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	a	_	DT	_	_	7	NMOD	_	_
4	West	_	NNP	_	_	5	AMOD	_	_
5	German	_	NNP	_	_	7	NMOD	_	_
6	pharmaceutical	_	JJ	_	_	7	NMOD	_	_
7	concern	_	NN	_	_	1	APPO	_	_
8	,	_	,	_	_	1	P	_	_
9	has	_	VBZ	_	_	0	ROOT	_	_
10	been	_	VBN	_	_	9	VC	_	_
11	discussing	_	VBG	_	_	10	VC	_	_
12	a	_	DT	_	_	13	NMOD	_	_
13	transaction	_	NN	_	_	11	OBJ	_	_
14	in	_	IN	_	_	18	LOC	_	_
15	which	_	WDT	_	_	14	PMOD	_	_
16	it	_	PRP	_	_	17	SBJ	_	_
17	would	_	MD	_	_	13	NMOD	_	_
18	buy	_	VB	_	_	17	VC	_	_
19	Delmed	_	NNP	_	_	20	NMOD	_	_
20	stock	_	NN	_	_	18	OBJ	_	_
21	for	_	IN	_	_	18	ADV	_	_
22	cash	_	NN	_	_	21	PMOD	_	_
23	to	_	TO	_	_	18	PRP	_	_
24	bring	_	VB	_	_	23	IM	_	_
25	its	_	PRP$	_	_	27	NMOD	_	_
26	beneficial	_	JJ	_	_	27	NMOD	_	_
27	ownership	_	NN	_	_	24	OBJ	_	_
28	to	_	TO	_	_	24	DIR	_	_
29	between	_	IN	_	_	31	DEP	_	_
30	70	_	CD	_	_	31	COORD	_	_
31	%	_	NN	_	_	28	PMOD	_	_
32	and	_	CC	_	_	31	COORD	_	_
33	80	_	CD	_	_	32	CONJ	_	_
34	%	_	NN	_	_	33	COORD	_	_
35	.	_	.	_	_	9	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	transaction	_	NN	_	_	4	SBJ	_	_
3	also	_	RB	_	_	4	ADV	_	_
4	would	_	MD	_	_	0	ROOT	_	_
5	combine	_	VB	_	_	4	VC	_	_
6	Fresenius	_	NNP	_	_	7	NAME	_	_
7	USA	_	NNP	_	_	5	OBJ	_	_
8	and	_	CC	_	_	7	COORD	_	_
9	Delmed	_	NNP	_	_	8	CONJ	_	_
10	.	_	.	_	_	4	P	_	_

1	But	_	CC	_	_	5	DEP	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	plan	_	NN	_	_	5	SBJ	_	_
4	now	_	RB	_	_	5	TMP	_	_
5	is	_	VBZ	_	_	12	OBJ	_	_
6	being	_	VBG	_	_	5	VC	_	_
7	``	_	``	_	_	6	P	_	_
8	reformulated	_	VBN	_	_	6	VC	_	_
9	,	_	,	_	_	12	P	_	_
10	''	_	''	_	_	12	P	_	_
11	Delmed	_	NNP	_	_	12	SBJ	_	_
12	said	_	VBD	_	_	0	ROOT	_	_
13	,	_	,	_	_	12	P	_	_
14	declining	_	VBG	_	_	12	ADV	_	_
15	to	_	TO	_	_	14	OPRD	_	_
16	provide	_	VB	_	_	15	IM	_	_
17	most	_	JJS	_	_	16	OBJ	_	_
18	of	_	IN	_	_	17	NMOD	_	_
19	the	_	DT	_	_	21	NMOD	_	_
20	new	_	JJ	_	_	21	NMOD	_	_
21	terms	_	NNS	_	_	18	PMOD	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	the	_	DT	_	_	24	NMOD	_	_
24	combination	_	NN	_	_	22	PMOD	_	_
25	.	_	.	_	_	12	P	_	_

1	Said	_	VBD	_	_	0	ROOT	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	spokeswoman	_	NN	_	_	1	SBJ	_	_
4	:	_	:	_	_	1	P	_	_
5	``	_	``	_	_	1	P	_	_
6	The	_	DT	_	_	8	NMOD	_	_
7	whole	_	JJ	_	_	8	NMOD	_	_
8	structure	_	NN	_	_	9	SBJ	_	_
9	has	_	VBZ	_	_	1	OBJ	_	_
10	changed	_	VBN	_	_	9	VC	_	_
11	.	_	.	_	_	1	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	value	_	NN	_	_	6	SBJ	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	company	_	NN	_	_	3	PMOD	_	_
6	has	_	VBZ	_	_	0	ROOT	_	_
7	changed	_	VBN	_	_	6	VC	_	_
8	.	_	.	_	_	6	P	_	_
9	''	_	''	_	_	6	P	_	_

1	Delmed	_	NNP	_	_	2	SBJ	_	_
2	did	_	VBD	_	_	0	ROOT	_	_
3	say	_	VB	_	_	2	VC	_	_
4	that	_	IN	_	_	3	OBJ	_	_
5	the	_	DT	_	_	6	NMOD	_	_
6	proposal	_	NN	_	_	8	SBJ	_	_
7	still	_	RB	_	_	8	ADV	_	_
8	would	_	MD	_	_	4	SUB	_	_
9	infuse	_	VB	_	_	8	VC	_	_
10	cash	_	NN	_	_	9	OBJ	_	_
11	into	_	IN	_	_	9	ADV	_	_
12	Delmed	_	NNP	_	_	11	PMOD	_	_
13	but	_	CC	_	_	14	DEP	_	_
14	less	_	JJR	_	_	9	PRN	_	_
15	than	_	IN	_	_	14	NMOD	_	_
16	the	_	DT	_	_	17	NMOD	_	_
17	$	_	$	_	_	15	PMOD	_	_
18	10	_	CD	_	_	17	DEP	_	_
19	million	_	CD	_	_	17	DEP	_	_
20	originally	_	RB	_	_	21	TMP	_	_
21	expected	_	VBN	_	_	17	APPO	_	_
22	.	_	.	_	_	2	P	_	_

1	Delmed	_	NNP	_	_	3	SBJ	_	_
2	also	_	RB	_	_	3	ADV	_	_
3	would	_	MD	_	_	0	ROOT	_	_
4	receive	_	VB	_	_	3	VC	_	_
5	the	_	DT	_	_	8	NMOD	_	_
6	North	_	NNP	_	_	8	NMOD	_	_
7	American	_	NNP	_	_	8	NMOD	_	_
8	rights	_	NNS	_	_	4	OBJ	_	_
9	to	_	TO	_	_	8	NMOD	_	_
10	certain	_	JJ	_	_	13	NMOD	_	_
11	Fresenius	_	NNP	_	_	13	NMOD	_	_
12	AG	_	NNP	_	_	13	NMOD	_	_
13	products	_	NNS	_	_	9	PMOD	_	_
14	.	_	.	_	_	3	P	_	_

1	Another	_	DT	_	_	2	NMOD	_	_
2	option	_	NN	_	_	10	SBJ	_	_
3	for	_	IN	_	_	2	NMOD	_	_
4	Delmed	_	NNP	_	_	3	PMOD	_	_
5	,	_	,	_	_	8	P	_	_
6	the	_	DT	_	_	7	NMOD	_	_
7	company	_	NN	_	_	8	SBJ	_	_
8	said	_	VBD	_	_	0	ROOT	_	_
9	,	_	,	_	_	8	P	_	_
10	is	_	VBZ	_	_	8	OBJ	_	_
11	that	_	IN	_	_	10	PRD	_	_
12	it	_	PRP	_	_	13	SBJ	_	_
13	could	_	MD	_	_	11	SUB	_	_
14	sell	_	VB	_	_	13	VC	_	_
15	its	_	PRP$	_	_	16	NMOD	_	_
16	plant	_	NN	_	_	14	OBJ	_	_
17	in	_	IN	_	_	16	LOC	_	_
18	Ogden	_	NNP	_	_	17	PMOD	_	_
19	,	_	,	_	_	18	P	_	_
20	Utah	_	NNP	_	_	18	APPO	_	_
21	.	_	.	_	_	10	P	_	_

1	It	_	PRP	_	_	2	SBJ	_	_
2	added	_	VBD	_	_	0	ROOT	_	_
3	that	_	IN	_	_	2	OBJ	_	_
4	no	_	DT	_	_	5	NMOD	_	_
5	discussions	_	NNS	_	_	10	SBJ	_	_
6	about	_	IN	_	_	5	NMOD	_	_
7	such	_	PDT	_	_	9	NMOD	_	_
8	a	_	DT	_	_	9	NMOD	_	_
9	sale	_	NN	_	_	6	PMOD	_	_
10	are	_	VBP	_	_	3	SUB	_	_
11	under	_	IN	_	_	10	PRD	_	_
12	way	_	NN	_	_	11	PMOD	_	_
13	.	_	.	_	_	2	P	_	_

